That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Hims & Hers Health appoints former Amazon executive Nader Kabbani as its chief operating officer. The telehealth-consultation platform on Monday said Kabbani will oversee operations as the company ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...